Seeing the light


The article 'Making Light Work' (Chemistry World, April 2012, p52) coincided with an alarming Daily Telegraph article relating the near-catastrophic increase in antibiotic resistance due to misuse by the NHS and in agriculture. It seems that big pharma is no longer interested in infection control for two reasons:

1 Any new antibiotic will quickly become ineffective due to acquired resistance.

2 They can make more money with continuous-use drugs to treat obesity, cholesterol and blood pressure than they can make on a 10-day course of antibiotics.

It is no great surprise that they are not interested in the potential of photodynamic therapy (PDT). The argument that they are not engineers is very negative, as in other fields of chemistry, such as cleaning and disinfection of food manufacturing equipment, it is routine for the chemical company to supply and service the dispensing equipment.

PDT is too good an opportunity to waste and there is a moral case for its commercialisation. I wonder if the experts in PDT would consider forming a cooperative organisation whereby professional scientists bought small shareholdings in the venture. I for one would be very happy to contribute a modest percentage of my pension.

M Barrett MRSC
Tewkesbury, UK


Related Content

Chemistry World podcast - October 2013

2 October 2013 Podcast | Monthly

news image

Chemists are helping palaeontologists discover the palette of fossil pigments, and helping toxicologists design greener compo...

Chemistry World podcast - February 2013

4 February 2013 Podcast | Monthly

news image

Graham Richards discusses crowdsourcing, Eric Wolff talks about ice cores and the team cover the latest chemical news

Most Read

Isotope effect produces new type of chemical bond

22 October 2014 Research

news image

Evidence emerges for vibrational bond first proposed 30 years ago

Not all science is created equal

16 October 2014 Comments

news image

John Ioannidis explains why researchers should be curious about the differences between disciplines

Most Commented

UCLA spent $4.5 million on legal costs in Sangji case

20 October 2014 News and Analysis

news image

University defends spending in case brought against chemistry professor, highlighting $20 million investment in lab safety

Not all science is created equal

16 October 2014 Comments

news image

John Ioannidis explains why researchers should be curious about the differences between disciplines